专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004085646A1 CYCLIC AMP RESPONSE ELEMENT ACTIVATOR PROTEINS AND USES RELATED THERETO 审中-公开
标题翻译：循环AMP反应元件激活蛋白及其相关用途
公开(公告)号：WO2004085646A1
公开(公告)日：2004-10-07
申请号：PCT/EP2004/003182
申请日：2004-03-25
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , IOURGENKO, Vadim , LABOW, Mark, Aron , SONG, Chuanzheng , ZHANG, Wenjun , ZHU, Jian
发明人： IOURGENKO, Vadim , LABOW, Mark, Aron , SONG, Chuanzheng , ZHANG, Wenjun , ZHU, Jian
IPC分类号： C12N15/12
CPC分类号： A61K38/1709 , C07K14/4705 , C12Q1/6883 , C12Q2600/158 , G01N2500/00
摘要： The invention discloses newly identified cyclic AMP response element activator proteins (CREAP proteins). It is contemplated herein that said proteins are suitable drug targets for the development of new therapeutics to prevent, treat or ameliorate pathological conditions related to abnormal activation of CRE-dependent gene expression or abnormal activation of chemokines. The invention relates to methods to prevent, treat or ameliorate said pathological conditions and pharmaceutical compositions therefor comprising modulators with inhibitory effect on CREAP protein activity and/or CREAP gene expression. The invention also relates to methods to identify compounds with therapeutic usefulness to treat said pathological conditions, comprising identifying compounds that can inhibit CREAP protein activity and/or CREAP gene expression.
摘要翻译：本发明公开了新鉴定的环AMP应答元件活化蛋白（CREAP蛋白）。本文预期所述蛋白质是用于开发新的治疗剂以预防，治疗或改善与CRE依赖性基因表达异常活化或趋化因子异常激活相关的病理状况的合适药物靶标。本发明涉及预防，治疗或改善所述病理状态的方法及其药物组合物，其包含对CREAP蛋白活性和/或CREAP基因表达具有抑制作用的调节剂。本发明还涉及鉴定具有治疗所述病理状况的治疗有效性的化合物的方法，其包括鉴定能抑制CREAP蛋白活性和/或CREAP基因表达的化合物。

2. 发明申请

WO2007095038A2 MUTATIONS AND POLYMORPHISMS OF ERBB2 审中-公开
标题翻译： ERBB2的突变和多态性
公开(公告)号：WO2007095038A2
公开(公告)日：2007-08-23
申请号：PCT/US2007/003305
申请日：2007-02-07
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , CULVER, Kenneth Wayne , ZHU, Jian , LILLEBERG, Stan
发明人： CULVER, Kenneth Wayne , ZHU, Jian , LILLEBERG, Stan
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/172
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the ERBB 2gene. The invention provides new ERBB2 mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the ERBB2 mutations of the invention, expression vectors encoding the ERBB2 mutant polypeptides of the invention and organisms that express the ERBB2 mutant and polymorphic polynucleotides and/or ERBB2 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the ERBB2 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
摘要翻译：本发明一般涉及体外组织样品的分析测试，更具体地涉及ERBB 2基因的遗传多态性和突变的方面。本发明提供了新的ERBB2突变和SNP，用于诊断和治疗有需要的受试者。因此，本发明的各个方面涉及编码本发明的ERBB2突变的多核苷酸，编码本发明的ERBB2突变体多肽的表达载体和表达ERBB2突变体的生物和表达ERBB2突变体和/或ERBB2突变体/多态多态的多态性发明。本发明的各个方面进一步涉及使用本发明的ERBB2突变和多态性的诊断/鉴别方法和试剂盒，以识别易患疾病的个体或在药物反应性，副作用或最佳药物剂量方面对个体进行分类。

3. 发明申请

WO2007016532A3 MUTATIONS AND POLYMORPHISMS OF HDAC4 审中-公开
公开(公告)号：WO2007016532A3
公开(公告)日：2007-02-08
申请号：PCT/US2006/029851
申请日：2006-07-31
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , CULVER, Kenneth, Wayne , ZHU, Jian , LILLEBERG, Stan
发明人： CULVER, Kenneth, Wayne , ZHU, Jian , LILLEBERG, Stan
IPC分类号： C12Q1/68 , A61K31/00
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the HDAC4 gene. The invention provides new HDAC4 mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the HDAC4 mutations of the invention, expression vectors encoding the HDAC4 mutant polypeptides of the invention and organisms that express the HDAC4 mutant and polymorphic polynucleotides and/or HDAC4 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the HDAC4 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.

4. 发明申请

WO2007109515A3 MUTATIONS AND POLYMORPHISMS OF KNOCKDOWN RESISTANCE POLYPEPTIDE 审中-公开
公开(公告)号：WO2007109515A3
公开(公告)日：2007-09-27
申请号：PCT/US2007/064115
申请日：2007-03-16
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , CULVER, Kenneth Wayne , ZHU, Jian , LILLEBERG, Stan
发明人： CULVER, Kenneth Wayne , ZHU, Jian , LILLEBERG, Stan
IPC分类号： C12Q1/68 , C07K14/71
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the KDR gene. The invention provides new KDR mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the KDR mutations of the invention, expression vectors encoding the KDR mutant polypeptides of the invention and organisms that express the KDR mutant and polymorphic polynucleotides and/or KDR mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the KDR mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.

5. 发明申请

WO2007095032A2 MUTATIONS AND POLYMORPHISMS OF PTK2B 审中-公开
标题翻译： PTK2B的突变和多态性
公开(公告)号：WO2007095032A2
公开(公告)日：2007-08-23
申请号：PCT/US2007/003280
申请日：2007-02-07
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , CULVER, Kenneth Wayne , ZHU, Jian , LILLEBERG, Stan
发明人： CULVER, Kenneth Wayne , ZHU, Jian , LILLEBERG, Stan
CPC分类号： C12Q1/6886 , C12N9/1205 , C12Q2600/106 , C12Q2600/172
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the PTK2B gene. The invention provides new PTK2B mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the PTK2B mutations of the invention, expression vectors encoding the PTK2B mutant polypeptides of the invention and organisms that express the PTK2B mutant and polymorphic polynucleotides and/or PTK2B mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the PTK2B mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
摘要翻译：本发明一般涉及体外组织样品的分析检测，更具体地涉及PTK2B基因的遗传多态性和突变的方面。本发明提供了新的PTK2B突变和SNP，其可用于诊断和治疗有需要的受试者。因此，本发明的各个方面涉及编码本发明的PTK2B突变的多核苷酸，编码本发明的PTK2B突变体多肽的表达载体和表达PTK2B突变体的生物和表达PTK2B突变体的多态性多核苷酸和/或PTK2B突变体/多态性多肽发明。本发明的各个方面还涉及使用本发明的PTK2B突变和多态性的诊断/诊断方法和试剂盒来鉴定易患疾病的个体或针对药物反应性，副作用或最佳药物剂量对个体进行分类。

6. 发明申请

WO2007058992A2 MUTATIONS AND POLYMORPHISMS OF HDAC6 审中-公开
标题翻译： HDAC6的突变和多态性
公开(公告)号：WO2007058992A2
公开(公告)日：2007-05-24
申请号：PCT/US2006/043899
申请日：2006-11-13
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , CULVER, Kenneth, Wayne , ZHU, Jian , LILLEBERG, Stan
发明人： CULVER, Kenneth, Wayne , ZHU, Jian , LILLEBERG, Stan
IPC分类号： A61K48/00 , A61K31/00 , C12N15/63 , A61P35/00
CPC分类号： A61K31/00 , A61K38/15 , A61K48/00 , C12Q1/6886
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the HDAC6 gene. The invention provides new HDAC6 mutations and SNPs5 useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the HDAC6 mutations of the invention, expression vectors encoding the HDAC6 mutant polypeptides of the invention and organisms that express the HDAC6 mutant and polymorphic ' polynucleotides and/or HDAC6 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the HDAC6 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
摘要翻译：本发明一般涉及体外组织样品的分析测试，并且更具体地涉及HDAC6基因的遗传多态性和突变的方面。本发明提供了用于诊断和治疗有需要的受试者的新的HDAC6突变和SNP5。因此，本发明的各个方面涉及编码本发明的HDAC6突变的多核苷酸，编码本发明HDAC6突变多肽的表达载体和表达HDAC6突变体和多态性'多核苷酸和/或HDAC6突变体/多态性多肽的有机体本发明。本发明的各个方面还涉及使用本发明的HDAC6突变和多态性鉴定易患疾病的个体或将个体分类为药物反应性，副作用或最佳药物剂量的诊断/诊断方法和试剂盒。

7. 发明申请

WO2007058991A2 MUTATIONS AND POLYMORPHISMS OF C-ABL 审中-公开
标题翻译： C-ABL的突变和多态性
公开(公告)号：WO2007058991A2
公开(公告)日：2007-05-24
申请号：PCT/US2006/043898
申请日：2006-11-13
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , CULVER, Kenneth, Wayne , ZHU, Jian , LILLEBERG, Stan
发明人： CULVER, Kenneth, Wayne , ZHU, Jian , LILLEBERG, Stan
IPC分类号： A61K48/00 , C12Q1/68 , A61P35/00 , A61K31/00 , C12N15/63
CPC分类号： A61K31/00 , C12N9/1205
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the c ABL gene. The invention provides new c ABL mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the c ABL mutations of the invention, expression vectors encoding the c ABL mutant polypeptides of the invention and organisms that express the c ABL mutant and polymorphic polynucleotides and/or c ABL mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the c ABL mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
摘要翻译：本发明一般涉及体外组织样品的分析测试，并且更具体地涉及c ABL基因的遗传多态性和突变的方面。本发明提供了用于诊断和治疗有需要的受试者的新的cABL突变和SNP。因此，本发明的各个方面涉及编码本发明的cABL突变的多核苷酸，编码本发明的cABL突变体多肽的表达载体和表达cABL突变体和多态性多核苷酸和/或cABL突变体/ 本发明的多态性多肽。本发明的各个方面还涉及诊断/诊断方法和试剂盒，其使用本发明的cABL突变和多态性来鉴定易患疾病的个体或关于药物响应性，副作用或最佳药物剂量对个体进行分类

8. 发明申请

WO2007053502A2 MUTATIONS AND POLYMORPHISMS OF HDAC5 审中-公开
标题翻译： HDAC5的突变和多态性
公开(公告)号：WO2007053502A2
公开(公告)日：2007-05-10
申请号：PCT/US2006/042187
申请日：2006-10-30
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , CULVER, Kenneth Wayne , ZHU, Jian , LILLEBERG, Stan
发明人： CULVER, Kenneth Wayne , ZHU, Jian , LILLEBERG, Stan
CPC分类号： A61K31/165 , A61K31/19 , A61K38/17
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the HDAC5 gene. The invention provides new HDAC5 mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the HDAC5 mutations of the invention, expression vectors encoding the HDAC5 mutant polypeptides of the invention and organisms that express the HDAC5 mutant and polymorphic polynucleotides and/or HDAC5 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the HDAC5 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
摘要翻译：本发明一般涉及体外组织样品的分析测试，更具体地涉及HDAC5基因的遗传多态性和突变的方面。本发明提供了可用于诊断和治疗有需要的受试者的新的HDAC5突变和SNP。因此，本发明的各个方面涉及编码本发明的HDAC5突变的多核苷酸，编码本发明的HDAC5突变体多肽的表达载体和表达HDAC5突变体的生物和表达HDAC5突变体和/或HDAC5突变体/多态性多态的多肽发明。本发明的各个方面进一步涉及使用本发明的HDAC5突变和多态性的诊断/诊断方法和试剂盒来鉴定易患疾病的个体或者关于药物反应性，副作用或最佳药物剂量对个体进行分类。

9. 发明申请

WO2007047998A3 MUTATIONS AND POLYMORPHISMS OF HDAC2 审中-公开
公开(公告)号：WO2007047998A3
公开(公告)日：2007-04-26
申请号：PCT/US2006/041168
申请日：2006-10-19
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , CULVER, Kenneth Wayne , ZHU, Jian , LILLEBERG, Stan
发明人： CULVER, Kenneth Wayne , ZHU, Jian , LILLEBERG, Stan
IPC分类号： A61K31/165 , C07K14/47 , C12Q1/68 , A61K31/19 , A61K38/17 , A61P35/00
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the HDAC2 gene. The invention provides new HDAC2 mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the HDAC2 mutations of the invention, expression vectors encoding the HDAC2 mutant polypeptides of the invention and organisms that express the HDAC2 mutant and polymorphic polynucleotides and/or HDAC2 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the HDAC2 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.

10. 发明申请

WO2007030455A2 MUTATIONS AND POLYMORPHISMS OF HDAC10 审中-公开
标题翻译： HDAC10的突变和多态性
公开(公告)号：WO2007030455A2
公开(公告)日：2007-03-15
申请号：PCT/US2006/034561
申请日：2006-09-05
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , CULVER, Kenneth Wayne , ZHU, Jian , LILLEBERG, Stan
发明人： CULVER, Kenneth Wayne , ZHU, Jian , LILLEBERG, Stan
IPC分类号： A61K31/4045 , A61K31/19 , A61K31/192 , A61K31/22
CPC分类号： A61K31/4045 , A61K31/16 , A61K31/167 , A61K31/19 , A61K31/192 , A61K31/22 , A61K31/277 , A61K31/336 , A61K31/351 , A61K31/403 , A61K31/407 , A61K31/4196 , A61K31/427 , A61K31/435 , A61K31/436 , A61K31/4406 , A61K31/473 , A61K31/4745 , A61K31/502 , A61K31/506 , A61K31/663 , A61K38/1709 , C12N9/16 , G01N33/57496 , G01N2333/916 , A61K2300/00
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the HDAC10 gene. The invention provides new HDAC10 mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the HDAC10 mutations of the invention, expression vectors encoding the HDAC10 mutant polypeptides of the invention and organisms that express the HDAC10 mutant and polymorphic polynucleotides and/or HDAC10 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the HDAC10 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
摘要翻译：本发明一般涉及体外组织样品的分析测试，更具体地涉及HDAC10基因的遗传多态性和突变的方面。本发明提供了可用于诊断和治疗有需要的受试者的新的HDAC10突变和SNP。因此，本发明的各个方面涉及编码本发明的HDAC10突变的多核苷酸，编码本发明的HDAC10突变体多肽的表达载体和表达HDAC10突变体的多态性和/或HDAC10突变体/多态性多肽的生物体发明。本发明的各个方面进一步涉及使用本发明的HDAC10突变和多态性的诊断/诊断方法和试剂盒来鉴定易患疾病的个体或在药物反应性，副作用或最佳药物剂量方面对个体进行分类。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式